AstraZeneca CEO Pascal Soriot reveals that artificial intelligence is revolutionizing drug development, enabling faster innovation and smarter decision-making. By leveraging AI tools and partnerships like Tempus AI, the company is significantly improving the odds of success in expensive clinical trials, leading to substantial productivity gains.
AstraZeneca CEO Pascal Soriot emphasized the profound impact of artificial intelligence (AI) on the pharmaceutical industry, stating that it is fundamentally reshaping drug development and significantly improving the odds of success in costly clinical trials.
"The value of AI in our industry is productivity improvement," Soriot explained during an appearance on CNBC's "Mad Money." He elaborated that AI tools enable drugmakers to design new medicines faster and with greater intelligence.
In an era where investors increasingly scrutinize the tangible returns of massive AI investments in sectors like healthcare, Soriot highlighted AstraZeneca's practical applications across various stages of drug discovery and development. This ranges from identifying novel drug targets to refining the design of potential medicines, making the process more efficient and effective.
"You can come up with new targets, but also you can optimize your molecule [and] remove what you think is going to be potential side effects from the molecule, and AI helps you do this," Soriot stated, detailing how AI assists in fine-tuning drug candidates.
Beyond initial discovery, AI is also instrumental in making critical decisions about which drugs to advance through the rigorous development pipeline. AstraZeneca's collaboration with Tempus AI, for instance, leverages advanced AI models to analyze complex clinical and laboratory data. The objective is to predict the probability of success for drugs entering Phase 3 trials, a stage known for its high costs and risks.
"We have developed an agent that takes all this data together — clinical data, laboratory data — and helps us predict the probability of success of a Phase 3 trial," Soriot added.
The financial implications of this enhanced predictive power are substantial. Given that a single Phase 3 trial can cost anywhere from "$300 million, $400 million, $500 million," as Soriot noted, even a slight increase in the probability of success translates into enormous productivity gains and significant cost savings for the company.
For more insights into market movements, consider signing up for the CNBC Investing Club.
Disclaimer: Questions for Cramer? Call Cramer: 1-800-743-CNBC. Connect on social media: Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram. For website feedback, email madcap@cnbc.com.
